Want a medical software business plan you can edit for your own business? Get the medical software business plan template and build it in the Toolkit.
Medical and health businesses carry a layer of licensing, compliance, and credentialing that most other sectors do not. The path from deciding to open a clinic to seeing your first patient takes longer than most founders expect, and undercapitalising that setup period is one of the most common reasons new practices fail.
This sample plan shows how a development-stage medical technology company funds its engineering years, wins its first device-maker partners, and projects the revenue ramp from first licences to royalties at volume.
See how Corvana Biosensing structures its plan and projects three years of revenue. Our Business Plan Toolkit gives you the same framework.
Executive Summary
Corvana Biosensing is a development stage venture based in Boston, Massachusetts, offering proprietary Digital Signal Processing (DSP) technology that dramatically improves the functionality and performance of biosensor devices. Corvana Biosensing’s core DSP algorithms solve a number of immediate problems in the medical devices market by significantly boosting the performance of biosensors without costly specialized hardware and additional chemicals. Initially, Corvana Biosensing will sell to medical device makers, specifically, home blood glucose monitors and hospital point-of-care blood analyzers. Corvana Biosensing anticipates achieving positive cash flow by year three with future target healthcare segments to include the large immunoassay and implantable biosensor sectors; as well as other vertical industries that heavily rely on biosensors, such as the military chemical agent detection, environmental air/water quality monitoring, and industrial processing sectors.
Financial highlights:
| Metric | Year 1 | Year 2 | Year 3 |
|---|---|---|---|
| Revenue | $142,000 | $683,500 | $1,948,000 |
| Gross margin | 71% | 78% | 83% |
| Net profit / (loss) | ($755,700) | ($672,500) | $35,900 |
Company Overview
Corvana Biosensing is a medical software business operating in Boston, Massachusetts. The business was established to license its DSP algorithms to medical device makers, improving biosensor performance without costly specialised hardware or additional chemicals.
Mission: To make biosensor devices more accurate and easier to use through signal processing software.
Business objectives:
| Period | Target |
|---|---|
| Year 1 | Complete development, sign the first licensing agreements with glucose monitor and point-of-care analyzer makers |
| Year 2 | Grow revenue several-fold as licensed products ship, add business development staff |
| Year 3 | Reach break-even and a first full-year profit, begin work on new biosensor segments |
Market & Customer Analysis
Industry context
When we last checked (October 2026), US health care spending reached $5.3 trillion in 2024, 18 percent of GDP (Centers for Medicare & Medicaid Services). Private clinics, therapy practices, home health agencies, and health technology businesses all operate within this market.
Software built into medical devices sits inside the device maker's regulatory submissions, so sales cycles are long and follow the partner's product timelines. Income comes from development fees and per-unit royalties once partner devices reach the market, which means a development-stage company funds engineering for well over a year before licensing revenue builds.
Investors in software licensing often look for gross margins of 70% or more, since there is little physical product to make. This plan starts at 71% in year one ($100,800 gross profit on $142,000 of revenue) and reaches 83% by year three.
The constraint is cash, not margin. Salaries of $612,400 in year one are more than four times revenue, and losses of $755,700 and $672,500 in the first two years add up to $1,428,200 that has to be funded before the $35,900 profit in year three. The plan puts this down to the development stage, when engineers are paid before partner devices ship.
Target customer profile
Corvana Biosensing's primary customers are medical device makers, starting with makers of home blood glucose monitors and hospital point-of-care blood analyzers. These companies want better sensor performance without the cost of specialised hardware or new test chemistry.
Competitor analysis:
| Competitor | Strengths | Weaknesses |
|---|---|---|
| In-house R&D teams at device makers | Direct control of the product and its regulatory file | Signal processing is rarely their core skill; slower to improve existing sensors |
| Specialised sensor hardware suppliers | Proven components already used in approved devices | Adds hardware cost to every unit sold |
| Test chemistry and reagent suppliers | Long relationships with device makers | Gains come from new chemicals, which add cost and testing |
Corvana Biosensing's advantage: Its DSP algorithms improve biosensor performance in software, without costly specialised hardware or additional chemicals.
SWOT analysis:
| Positive | Negative | |
|---|---|---|
| Internal | Strengths: Proprietary DSP algorithms; experienced founding team; software-only improvement with no added hardware | Weaknesses: Development stage with no shipped products yet; long partner sales cycles; losses in the first two years |
| External | Opportunities: Immunoassay and implantable biosensors; military, environmental and industrial sensing | Threats: Device makers building similar software in-house; partner product delays; competing sensor technologies |
Sales & Marketing Plan
Corvana Biosensing reaches its target customers through direct outreach to medical device makers. The primary channels are direct sales to product and engineering teams, medical device trade shows, and referrals from early licensing partners.
Pricing approach: Licensing agreements combine development fees with per-unit royalties on partner devices. Terms are agreed in writing before integration work begins.
Sales process:
- Introductory meeting with a device maker's product and engineering teams
- Technical evaluation of the algorithms on the partner's sensor data
- Licensing proposal covering development fees and royalties
- Licensing agreement signed and integration work scheduled
- Algorithms integrated and supported through the partner's product launch
Operating Plan
Corvana Biosensing operates from Boston, Massachusetts with a lean engineering team. Standard operating procedures cover algorithm development, partner integration, quality review, and partner communication.
Staffing plan:
| Role | Year 1 | Year 2 | Year 3 |
|---|---|---|---|
| Founder / Managing Director | 1 | 1 | 1 |
| DSP and software engineers | 4 | 6 | 8 |
| Business development / licensing | 0 | 1 | 2 |
| Administration / support | 1 | 1 | 1 |
Key suppliers and partnerships: Corvana Biosensing works closely with its device-maker partners and uses outside testing and regulatory specialists where a partner's product submission needs them.
Management Team
The founding team of Corvana Biosensing brings relevant industry experience and a clear understanding of the target market. The founder has held senior roles in medical device and signal processing development prior to starting the business and brings both technical expertise and commercial knowledge to the leadership of the organisation.
Hiring plan: As the business grows, the priority is to hire people who share the company's commitment to quality and client service. The business will promote from within where possible and invest in staff development to reduce turnover.
Financial Plan
3-year profit and loss projection:
| Year 1 | Year 2 | Year 3 | |
|---|---|---|---|
| Revenue | $142,000 | $683,500 | $1,948,000 |
| Clinical supplies and direct labour | $41,200 | $150,400 | $331,200 |
| Gross profit | $100,800 | $533,100 | $1,616,800 |
| Gross margin | 71% | 78% | 83% |
| Salaries and wages | $612,400 | $874,300 | $1,146,700 |
| Marketing and advertising | $38,600 | $76,200 | $118,400 |
| Rent and utilities | $61,800 | $68,900 | $74,300 |
| Other operating costs | $143,700 | $186,200 | $241,500 |
| Total operating expenses | $856,500 | $1,205,600 | $1,580,900 |
| Net profit / (loss) | ($755,700) | ($672,500) | $35,900 |
Break-even analysis:
- Estimated monthly fixed costs: $71,400
- Monthly revenue required to break even: $100,600
- Break-even is projected during the third year of trading.
Ready to write yours? Open the medical software business plan template, fill in your figures and export it.